Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma

Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma

Multiple myeloma (MM) remains an incurable tumor due to the high rate of relapse that still occurs. Acquired drug resistance represents the most challenging obstacle to the extension of survival and several studies have been conducted to understand the mechanisms of this phenomenon. Mitochondrial pa...

Full description

Bibliographic Details
Main Authors:	Vanessa Innao, Vincenzo Rizzo, Andrea Gaetano Allegra, Caterina Musolino, Alessandro Allegra
Format:	Article
Language:	English
Published:	MDPI AG 2021-02-01
Series:	Cells
Subjects:	multiple myeloma drug resistance mitochondrial-resistance chemotherapy apoptosis
Online Access:	https://www.mdpi.com/2073-4409/10/2/439

Similar Items

Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs
by: Vanessa Innao, et al.
Published: (2021-12-01)

Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies
by: Andrea Gaetano Allegra, et al.
Published: (2020-11-01)

Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
by: Alessandro Allegra, et al.
Published: (2019-06-01)

Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation
by: Gabriele Buda, et al.
Published: (2021-08-01)

Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma
by: Giuseppe Murdaca, et al.
Published: (2021-08-01)

Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma
by: Alessandro Allegra, et al.
Published: (2019-03-01)

Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells
by: Cesarina Giallongo, et al.
Published: (2020-07-01)

Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma
by: Alessandro Allegra, et al.
Published: (2021-02-01)

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
by: Zhihong Zheng, et al.
Published: (2018-02-01)

Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
by: Lisa C. Holthof, et al.
Published: (2020-04-01)

Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells
by: Zsolt Matula, et al.
Published: (2021-07-01)

New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges
by: Alessandro Allegra, et al.
Published: (2021-04-01)

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
by: Ying Chen, et al.
Published: (2020-05-01)

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
by: Lorraine N. Davis, et al.
Published: (2021-04-01)

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
by: Ying Chen, et al.
Published: (2021-07-01)

Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies
by: Vanessa Innao, et al.
Published: (2021-05-01)

EXPRESSION OF GENES RESPONSIBLE FOR MULTIDRUG RESISTANCE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
by: Yu. B. Chernykh, et al.
Published: (2016-02-01)

Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma
by: Caterina Musolino, et al.
Published: (2017-01-01)

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma
by: Phuong Nguyen, et al.
Published: (2019-10-01)

Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells
by: Jahangir Abdi, et al.
Published: (2019-10-01)

Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma
by: Machin, Reinaldo Franqui
Published: (2018)

New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era
by: Vanessa Innao, et al.
Published: (2020-11-01)

Chromothripsis in Treatment Resistance in Multiple Myeloma
by: Kyoung Joo Lee, et al.
Published: (2017-09-01)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
by: Sang Wu Lee, et al.
Published: (2021-01-01)

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
by: Marilina García-Aranda, et al.
Published: (2018-12-01)

Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
by: Omar S. Al-Odat, et al.
Published: (2021-07-01)

Targeting Nuclear Factor-kappa B to overcome resistance to chemotherapy.
by: Peter eGodwin, et al.
Published: (2013-05-01)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
by: Joel G. Turner, et al.
Published: (2016-08-01)

Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
by: Frontiers Production Office
Published: (2021-08-01)

Historical perspective and advances in the treatment of multiple myeloma
by: Amir Harandi, et al.
Published: (2011-12-01)

Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma Cells
by: Yi Zhao, et al.
Published: (2018-07-01)

Multiple Myeloma: Available Therapies and Causes of Drug Resistance
by: Vanessa Pinto, et al.
Published: (2020-02-01)

Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma
by: Yao R, et al.
Published: (2020-09-01)

Serum Levels of Vitamin D in Patients with Multiple Myeloma
by: Vasko Graklanov, et al.
Published: (2020-12-01)

Hypoxia: Progressive Multiple Myeloma and Its Therapy Resistance
by: Ogechi Charity Obayi, et al.
Published: (2021-04-01)

Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma
by: Mengjie Guo, et al.
Published: (2021-04-01)

The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma
by: Laure Maneix, et al.
Published: (2021-02-01)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
by: Thumallapally N, et al.
Published: (2016-08-01)

Carfilzomib boosted combination therapy for relapsed multiple myeloma
by: Steiner RE, et al.
Published: (2017-02-01)

Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer
by: Martina Godel, et al.
Published: (2021-05-01)